ADHD News From Medical News Today

Are The Monoamines Involved In Shaping Conduct Disorders?Antisocial and aggressive behaviours represent a widespread and expensive social problem. Recent research has convincingly shown that there is a strong interaction between genetic inheritance and environment for development of personality and behaviour. It appears to be common knowledge that childhood maltreatment often causes psychiatric problems (e.g. depression or anxiety) or behavioural problems (e.g. aggression or antisocial behaviour) later in life.10 Grants Awarded By The Robert Wood Johnson Foundation Investigator Awards In Health Policy ResearchIn an effort to tackle major health policy issues in the United States, the Robert Wood Johnson Foundation® (RWJF) has announced the selection of this year's recipients of its Investigator Awards in Health Policy Research. Sixteen scholars affiliated with major universities across the country will receive funding to support 10 new research projects.Shire Announces FDA Approval Of Once-Daily INTUNIV™ Extended Release Tablets For The Treatment Of ADHD In Children And Adolescents Aged 6 To 17Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV™ (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.INTUNIV (Guanfacine) Extended Release Tablets For ADHD In Children And Adolescents Approved By FDAShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV™ (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.Shire Announces FDA Approval Of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets For The Treatment Of ADHD In Children And AdolescentsShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.More Kids Using ADHD Drugs To Get HighAttention-deficit/hyperactivity disorder (ADHD) affects between 8 percent and 12 percent of children and 4 percent of adults worldwide. There has been a significant increase in the use of prescription stimulants to treat ADHD. The most frequently prescribed ADHD medications include mixed amphetamine salts and methylphenidate.Back-to-School Resource From American Public University For Teachers, Counselors: 'Tips' Cards On ADD/ADHD, Bullying, Child Abuse, Teen Depression "Tips for Teachers" cards on key behavioral and student wellness issues are available at no cost to teachers, counselors, principals and other school-based personnel, thanks to a program by American Public University, a member institution of American Public University System, an accredited, online university system that serves more than 50,000 working adults studying worldwide.Do Brain Waves Run Our Attention Clock? New research from the US suggests that when we look for something in our environment, our attention scans one thing at a time, using a serial as opposed to a parallel process whose clock speed is controlled by brain waves or "neuron population oscillations".Study Demonstrated Once-Daily Vyvanse® CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After AdministrationShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.Study Demonstrated Once-Daily Vyvanse(R) CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After Administration Shire plc announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration.FDA Issues Complete Response Letter For INTUNIV™ (guanfacine) Extended Release For The Treatment Of ADHD In Children And AdolescentsShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter for INTUNIV TM (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date. The FDA did not identify safety concerns regarding INTUNIV in the Complete Response letter or request new clinical studies.FDA Issues Complete Response Letter For INTUNIV(TM) (guanfacine) Extended Release For The Treatment Of ADHD In Children And AdolescentsShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date.Vyvanse CII Significantly Improved ADHD Symptoms For Children 13 Hours After AdministrationShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.New Research Evaluates The Impact Of Working Memory Training And Stimulant Medication On Kids With ADHD A study to be published in the August 2009 edition of Applied Cognitive Psychology sheds new light on how Cogmed Working Memory Training and stimulant medication address working memory impairments in children with ADHD. Working memory, acknowledged as one of the core deficits in ADHD, represents the brain's ability to hold and process critical information related to the present moment.Children With Fetal Alcohol Spectrum Disorders Have More Severe Behavioral Problems Than Those With ADHDChildren with fetal alcohol spectrum disorders (FASD) have a high risk of psychiatric problems, particularly attention deficit hyperactivity disorder (ADHD), conduct disorder, or both. Often children with FASD are initially diagnosed with ADHD. A new study is the first to examine a range of cognitive factors and social behavior in children with FASD and ADHD, finding that those with FASD have significantly weaker social cognition and facial emotion-processing abilities.New Research Shows: Neurofeedback Is An 'Evidence-Based' Treatment For ADHDNeurofeedback - also called EEG Biofeedback - is a method used to train brain activity in order to normalize Brain function and treat psychiatric disorders. This treatment method has gained interest over the last 10 years, however the question whether this treatment should be regarded as an Evidence-Based treatment was unanswered until now.Aiming For Early Diagnosis For ADHD And Parkinson's DiseaseEye movement tests developed by Queen's University researchers to aid in understanding childhood brain development and healthy aging may also help in the diagnosis of Attention Deficit Hyperactivity Disorder and detecting the early onset of Parkinson's disease. The project has received close to $1 million in recent funding from the Canadian Institutes of Health Research (CIHR).The Role Of Genetic Factors In Adult ADHD22nd Congress of the European College of Neuropsychopharmacology (ECNP), 12 - 16 September 2009, Istanbul, Turkey Dr. Barbara Franke, who is coordinating the International Multicentre persistent ADHD CollaboraTion (IMpACT) will present the latest findings in the identification of risk genes for ADHD.Targacept Announces Decision By AstraZeneca To Advance AZD3480 Program In ADHDTargacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that AstraZeneca has informed Targacept that it plans to conduct further development of AZD3480 (TC-1734) for attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment to Targacept. AstraZeneca also confirmed plans to continue development of AZD1446 (TC-6683) for Alzheimer's disease.Consumer Reports To Parents: Think Twice About Free Prescription ADHD Drug Samples For Your ChildrenAccording to a new Consumer Reports Best Buy Drugs report, parents should be skeptical if their doctors offer them free prescription drug samples, especially for the treatment of attention deficit hyperactivity disorder (ADHD). Free samples can hook consumers on high-priced brand name drugs that are not any better or safer than less expensive generic medicines.VYVANSE CII Provided Significant Efficacy At 14 Hours After Administration In Adults With ADHD In An Adult Simulated Workplace EnvironmentShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).New Goal To Get More People With Learning Disabilities Into Work, UKPeople with a learning disability will be helped into paid jobs to close the employment gap, Jonathan Shaw, Minister for Disabled People and Phil Hope, Minister for Care Services pledged today. The goal is set out in the new cross-government Learning Disability Employment Strategy, published today. The strategy sets out a vision to increase the number of real jobs for people with learning disabilities with appropriate support being provided.ADHD Genes Found; Known To Play Roles In NeurodevelopmentPediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were already known to be important for learning, behavior, brain function and neurodevelopment, but had not been previously associated with ADHD.Do ADHD Drugs Cause Sudden Death? This week, a study came out that scared us big-time ... it suggests that children and teens who take stimulants like Ritalin for ADHD have an increased risk for sudden cardiac death. Our pediatrician weighs in. A new study in The American Journal of Psychiatry suggests that children and teens who take stimulants like Ritalin for ADHD have an increased risk for sudden cardiac death.Study Links ADHD Drugs To Sudden Death In Children A new study by researchers in the US suggests there may be a link between the use of stimulant drugs for attention-deficit hyperactivity disorder (ADHD) and sudden cardiac death in healthy children, but the US Food and Drug Administration (FDA), who funded the study with the National In

This Post is Powered By

RssFeeds.Qsh.Eu